| Literature DB >> 28228488 |
Alenka J Brooks1,1, Philip J Smith2,1, Richard Cohen3, Paul Collins4, Andrew Douds5, Valda Forbes6, Daniel R Gaya7, Brian T Johnston8, Patrick J McKiernan9, Charles D Murray2, Shaji Sebastian10, Monica Smith11, Lisa Whitley12, Lesley Williams13, Richard K Russell14, Sara A McCartney15, James O Lindsay16,17.
Abstract
The risks of poor transition include delayed and inappropriate transfer that can result in disengagement with healthcare. Structured transition care can improve control of chronic digestive diseases and long-term health-related outcomes. These are the first nationally developed guidelines on the transition of adolescent and young persons (AYP) with chronic digestive diseases from paediatric to adult care. They were commissioned by the Clinical Services and Standards Committee of the British Society of Gastroenterology under the auspices of the Adolescent and Young Persons (A&YP) Section. Electronic searches for English-language articles were performed with keywords relating to digestive system diseases and transition to adult care in the Medline (via Ovid), PsycInfo (via Ovid), Web of Science and CINAHL databases for studies published from 1980 to September 2014. The quality of evidence and grading of recommendations was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The limited number of studies in gastroenterology and hepatology required the addition of relevant studies from other chronic diseases to be included.These guidelines deal specifically with the transition of AYP living with a diagnosis of chronic digestive disease and/or liver disease from paediatric to adult healthcare under the following headings;1. Patient populations involved in AYP transition2. Risks of failing transition or poor transition3. Models of AYP transition4. Patient and carer/parent perspective in AYP transition5. Surgical perspective. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.Entities:
Keywords: GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASE; LIVER; PAEDIATRIC GASTROENTEROLOGY
Mesh:
Year: 2017 PMID: 28228488 PMCID: PMC5532456 DOI: 10.1136/gutjnl-2016-313000
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 23.059
Individual studies included in the guideline are formally assessed using the GRADE system1 with the quality of the body evidence rated, from ‘high’ (A) to ‘very low’ (D)
| Modify the initial quality of a body of evidence | ||||
|---|---|---|---|---|
| Study design | Initial quality of a body of evidence | Rate lower if | Rate higher if | Quality of body of evidence |
| Randomised controlled trials | High★★★★ | High (A)★★★★ | ||
| Moderate (B)★★★ | ||||
| Observational studies/qualitative studies | Low★★ | |||
| +1 would reduce a demonstrated effect | Low (C)★★ | |||
| +1 would suggest a spurious effect if no effect observed | Very low (D) ★ | |||
Guideline recommendations are classified as either strong or weak by determining the balance of desirable and undesirable outcomes using the GRADE system1
| Rating the strength of a recommendation: balancing desirable and undesirable outcomes | |
|---|---|
| Strong recommendation | Weak recommendation |
| Desirable outcomes +++ > undesirable outcomes + | Desirable outcomes ++ > undesirable outcomes + |
| Examples of desirable outcomes | Examples of undesirable outcomes |
|
Increased longevity Reduction in morbid events intervention designed to prevent Resolution of symptoms Improved quality of life Decreased resource use |
Decreased longevity Immediate serious complications Short-term relatively minor side effects Long-term rare serious adverse events Impaired quality of life Inconvenience/hassle Increased resource use |
The estimated (and extrapolated) UK prevalence of chronic paediatric GI/liver conditions and number of patients transitioned each year using the best available epidemiological, audit and survey data as well as expert opinion
| GI/liver condition | UK paediatric prevalence (total population or proportion within populations) | Estimated number of patients transitioned per year |
|---|---|---|
| IBD* | 7000 | 1000 (∼60% Crohn's disease) |
| Chronic liver disease | The prevalence of paediatric liver disease in England between 2008 and 2014: | Approximately 61–76 transplant cases per annum‡ |
| Complex enteral | No relevant data identified | No relevant data identified |
| Parenteral nutrition (combination of long term in and out of hospital) | 290§ | 60 |
| Coeliac disease | 3–13 per 1000 children, or approximately 1:80 to 1:300 children | 600 per year |
| Allergic/eosinophilic oesophagitis | Food allergy 0.6% | No specific data |
| Functional GI disease | ∼10% | No specific data |
*Estimates derived from the organisational IBD audit 2013 and local figures (RKR).
†Williams et al.17
‡Data from annual report on liver transplantation NHS England September 2014 (2004–2014).
§Data courtesy of Henry Gowens/Andy Barclay British Intestinal Failure Survey data (unpublished 2014).
Figure 1Diagrammatic illustration of the different components an effective transition model should include.
Figure 2A transition pathway from paediatric to adult care for adolescent and young person (AYP) patients with chronic digestive disorders. MDT, multidisciplinary team.